Skip to main content
Premium Trial:

Request an Annual Quote

Exagen Diagnostics Raises $5M

NEW YORK (GenomeWeb News) – Exagen Diagnostics this week said in a regulatory filing that it raised a little more than $5 million in an equity financing round.

A spokesperson for the Albuquerque, NM-based firm declined to comment on the raise. In its document filed with the US Securities and Exchange Commission, Exagen did not disclose the investors or say how the proceeds would be used.

According to Exagen's website, it uses a technology dubbed Coperna to identify and validate small sets of genomic biomarkers for use in diagnostic tests run out of its CLIA laboratory in Vista, Calif. Coperna is a computational engine that identifies markers across "the spectrum of genomic data types," Exagen said, including high-density gene expression and SNP arrays.

A year ago, it received State of New York approval for its Avise SLE diagnostic test called SLE-Systemic Lupus Erythematosus. In September 2012, the company raised $5.3 million in a financing round.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.